Predictive biomarkers of early allograft dysfunction after liver transplantation: A prospective pilot study

Table 1 Baseline characteristics of static cold storage recipients by early allograft dysfunction status, n (%)

Variable	Subset	Non-EAD (n = 16)	EAD (n = 8)
Donor age	Median (IQR)	41.5 (30.5, 52)	55.5 (38, 61.5)
Donor mode of death	DCD	2 (13)	1 (13)
	ECD	2 (13)	1 (13)
	SCD	12 (74)	6 (74)
Recipient age	Median (IQR)	58 (43, 64)	59 (51.5, 63.5)
Recipient gender	Female	8 (50)	3 (38)
	Male	8 (50)	6 (62)
BMI	Median (IQR)	25.5 (23.5, 30)	34 (32.5, 36)
MELD score	Median (IQR)	24.5 (18, 35)	28 (27, 35)
Primary ESLD etiology	Acute liver failure	2 (12)	1 (12)
	Alcohol-related cirrhosis	5 (32)	0
	Autoimmune	0 (0)	1 (12)
	Graft failure	1 (6)	0
	HCC	1 (6)	0
	HCV	0	3 (38)
	MASH	4 (25)	3 (38)
	PBC	1 (6)	0
	PSC	2 (12)	0
Comorbidities	No	2 (12)	2 (25)
Hepatic encephalopathy	Yes	14 (88)	6 (75)
Hepatopulmonary syndrome	No	12 (75)	7 (88)
	Yes	4 (25)	1 (12)
Non-obstructive CAD	No	11 (69)	5 (63)
	Yes	5 (31)	3 (37)
Obstructive CAD	No	16 (100)	7 (88)
	Yes	0	1 (12)
Hepatorenal syndrome	No	10 (63)	5 (63)
	Yes	6 (37)	3 (37)
Esophageal varices	No	5 (31)	4 (50)
	Yes	11 (69)	4 (50)
Ascites	No	4 (25)	3 (38)
	Yes	12 (75)	5 (62)
Hypertension	No	0	0
	Yes	16 (100)	8 (100)
Pre-operative laboratory values:
Creatinine (mg/dL)	Median (IQR)	0.95 (0.72, 1.33)	1.11 (0.84, 1.53)
INR	Median (IQR)	1.72 (1.48, 2.76)	1.36 (1.1, 2.25)
Hemoglobin (g/dL)	Median (IQR)	9.45 (8.9, 12.25)	10.9 (8.7, 13.05)
Platelets (109/L)	Median (IQR)	82 (62, 118)	88 (62.5, 127.5)
Fibrinogen (mg/dL)	Median (IQR)	169 (137, 138)	204.5 (122.5, 301.5)
Total ischemia time (hours)	Median (IQR)	6.42 (5.17, 7.18)	6.17 (4.64, 8.07)
Cold ischemia (hours)	Median (IQR)	5.81 (4.59, 6.69)	5.71 (3.9, 7.49)
Warm ischemia (minutes)	Median (IQR)	32.5 (29, 37.5)	35 (28, 48)
Inferior vena cava clamp type	Piggyback	16 (100)	6 (75)
	Total cross clamp	0	2 (25)
Day 7 INR	Median (IQR)	1.03 (0.94, 1.1)	1.17 (1.05, 1.47)
Day 7 total bilirubin (mg/dL)	Median (IQR)	2.05 (0.85, 4.25)	2.55 (2.1, 5.1)
Peak 7-day AST (U/L)	Median (IQR)	997 (609, 1509.5)	3215 (2413, 6318)
Peak 7-day ALT (U/L)	Median (IQR)	482 (230, 957.5)	1304 (543, 1948)
Methylprednisolone exposure (relative to T2)	Before	6 (38)	3 (38)
	After	10 (62)	5 (62)
Received basiliximab		8 (50)	4 (50)
Basiliximab exposure (relative to T2)	Before	3 (37)	1 (25)
	After	5 (62)	3 (75)

AST: Aspartate transaminase; ALT: Alanine transaminase; INR: International normalized ratio; SCDs: Standard criteria donors; ESLD: End-stage liver disease; MASH: Metabolic dysfunction-associated steatohepatitis; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; MELD: Model for end-stage liver disease; EAD: Early allograft dysfunction; IQR: Interquartile ranges; DCD: Donation after circulatory death; ECD: Extended criteria donor; BMI: Body mass index; PBC: Primary biliary cirrhosis; PSC: Primary sclerosing cholangitis; CAD: Coronary artery disease.